TRANSFER LEARNING

DISCOVERY TEST DISCOVERY TEST

patient count (n)		Radiotherapy			Surgery			Stability	Totals
		Training	Tuning	Testing	Training	Tuning	Testing		
cohort		HarvardRT	Radboud	Maastro	Moffitt	MUMC	M-SPORE	Rider	
NSCLC + Stages 1, 2 & 3 + has survival data		317	147	307	200**	90**	101	32	**1194**
has 2 year survival data		293	104	211*	183	88	97	0	976
has engineered features		291	104	210	183	88	97	0	973
survival median - years		2.18	0.9	1.04	2.83	3.26	4.5		
2-year survival	deceased	134	76	151	50	24	17		
	alive	159	28	60	133	64	80		
age median - years		69.6	65.9	69	n/a	68	70		
gender	male	140	n/a	142	83	61	44		
	female	153	n/a	69	100	27	53		
TNM staging	stage I (%)	102(34.8)	6(5.8)	36(17.1)	106(58)	47(53.4)	62(64)		
	stage II (%)	18(6.1)	11(10.6)	19(9)	34(18.6)	22(25)	15(15.5)		
	stage III (%)	173(59)	87(83.7)	156(74)	43(23.5)	19(21.6)	20(20.6)		
histology	Adenocarcinoma (%)	180(61.4)	34(32.7)	30(14.2)	114(62.3)	43(48.9)	97(100)		
	Squamous cell Carcinoma (%)	65(22.2)	42(40.4)	101(47.9)	57(31.1)	37(42)	0		
	Large cell Carcinoma (%)	46(15.7)	24(23.1)	80(37.9)	2(1.1)	1(1.1)	0		
	NSCLC NOS (%)	2(1)	4(3.8)	0	10(5.5)	7(8)	0		

Used in deep learning models

Used in survival separation assessment (Kaplan-Meier curves)

Used in engineered imaging models, clinical models and combined models

Used in test-retest stability assessment

* Used in input variation stability assessment

** Used in genomic assocciation studies